Novo Nordisk says its obesity drug in higher dose shows 20.7% weight loss
Novo Nordisk said on Friday a late-stage trial with a high-dose version of its weight loss drug semaglutide helped overweight ...
How Trump’s Greenland demands could impact Ozempic costs
President-elect Trump’s threat to tariff Denmark if it resists his acquisition plans for the island territory of Greenland ...
Trump’s plan to impose tariffs in bid to acquire Greenland could raise prices of Ozempic, Legos
President-elect Donald Trump’s threat to slap Denmark with tariffs to force its hand in giving up Greenland could lead to ...
Yahoo29d
An experimental drug drove people to lose 23% of their body weight. It’s still seen as a disappointment
Novo Nordisk CEO Lars Fruergaard Joergensen in December during a presentation of a new production site. The company's latest attempt at a weight loss drug, CagriSema, matched the bar set by a ...
New York Post29d
Novo Nordisk shares plummet after weight-loss drug’s disappointing trial results
Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its market value.